Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Rare Tumour × camrelizumab × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Hepatocellular 32 Carcinoma, Non-Small-Cell Lung 22 Triple Negative Breast Neoplasms 19 Nasopharyngeal Carcinoma 18 Stomach Neoplasms 17 Esophageal Neoplasms 17 Esophageal Squamous Cell Carcinoma 16 Squamous Cell Carcinoma of Head and Neck 14 Breast Neoplasms 13 Colorectal Neoplasms 11 Uterine Cervical Neoplasms 10 Recurrence 7 Neoplasm Metastasis 7 Sarcoma 6 Pancreatic Neoplasms 6 Melanoma 6 Liver Neoplasms 5 Biliary Tract Neoplasms 5 Small Cell Lung Carcinoma 4 Neoplasms 4 Lung Neoplasms 4 Hodgkin Disease 4 Cholangiocarcinoma 4 Advanced Gastric Cancer 4 Solid Tumor 3 Rectal Neoplasms 3 Parkinson Disease 4, Autosomal Dominant Lewy Body 3 Osteosarcoma 3 Nasopharyngeal Neoplasms 3 Locally Advanced Gastric Cancer 3

Interventions

toripalimab 1 tislelizumab 1 sintilimab 1 pyrotinib 1 pembrolizumab 1 pamiparib 1 palbociclib 1 osimertinib 1 neratinib 1 erdafitinib 1 envafolimab 1 entrectinib 1 durvalumab 1 camrelizumab 1 atezolizumab 1 alectinib 1 Vinorelbine 1 Vemurafenib 1 Teniposide 1 Nivolumab 1 Irinotecan 1 Imatinib Mesylate 1 Gemcitabine 1 Fluorouracil 1 Epirubicin 1 Cisplatin 1 Albumin-Bound Paclitaxel 1 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06692491 2024-11-18

SPRING

Peking University Shenzhen Hospital

Phase 2 Not yet recruiting

Rare Tumour

Data powered by HemOnc (CC BY 4.0) Colophon ⚡